|
|
Volumn 23, Issue 3, 2005, Pages 272-273
|
|
Cost-effectiveness data on biologics needed
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIHYPERTENSIVE AGENT;
BIOLOGICAL PRODUCT;
DRUG;
BIOTECHNOLOGY;
COST CONTROL;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG MARKETING;
HEALTH CARE DELIVERY;
HEALTH ECONOMICS;
HUMAN;
HYPERTENSION;
INSOMNIA;
MANAGED CARE ORGANIZATION;
MEDICAID;
MEDICARE;
NOTE;
PHARMACY BENEFIT MANAGER;
PRIORITY JOURNAL;
PSORIASIS;
QUALITY ADJUSTED LIFE YEAR;
REIMBURSEMENT;
SOCIOECONOMICS;
TREATMENT OUTCOME;
ARTICLE;
COST BENEFIT ANALYSIS;
DRUG INDUSTRY;
DRUG THERAPY;
ECONOMICS;
EUROPEAN UNION;
METHODOLOGY;
STATISTICAL MODEL;
UNITED STATES;
BIOLOGICAL PRODUCTS;
COST-BENEFIT ANALYSIS;
DRUG INDUSTRY;
DRUG THERAPY;
EUROPEAN UNION;
MODELS, ECONOMIC;
PHARMACEUTICAL PREPARATIONS;
UNITED STATES;
|
|
EID: 21444435661
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt0305-272 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|